Oleh:
M. Chairil Riskyta Akbar
Pembimbing:
dr. Hawaidah, Sp.KJ (K)
0
LEMBAR PENGESAHAN
1
DAFTAR ISI
Halaman Pengesahan…………………………………………...………….. 1
Daftar Isi…………………………………………………………………… 2
Bab I Pendahuluan………………………………………………………… 3
1. Definisi……………………………………………………………...5
2. Epidemiologi………………………………………………………..5
3. Etiologi & Faktor resiko…………………………………………. 6
4. Gambaran Klinis……………………………………………….… 8
5. Diagnosis………………………………………………………….. 8
6. Penatalaksanaan…………………………………………………….12
7. Prognosis...........……………………………………..………….......14
Daftar Pustaka………….………………………….……………………….. 17
2
BAB I
PENDAHULUAN
Psikosis merupakan komplikasi berat dari epilepsi meskipun jarang
ditemukan. Keadaan ini disebut dengan psychoses of epilepsy (POE) (Israr, 2009).
Psikosis pada pasien epilepsi digolongkan berdasarkan hubungan temporal gejala
itu dengan kejang. Beberapa penelitian lain memperlihatkan bahwa gejala psikosis
pada pasien epilepsi umum cenderung singkat dan pasien cenderung bingung.
Tidak ada kesepakatan yang ada diterima secara internasional dalam hal
pengklasifikasian sindrom psikosis pada epilepsi.
3
BAB II
TINJAUAN PUSTAKA
A. Definisi
Psikosis merupakan keadaan gangguan jiwa yang berat dimana
penderita kehilangan pandangan mengenai realitas. Psikosis merupakan
komplikasi berat dari epilepsi meskipun jarang ditemukan. Keadaan ini
disebut dengan psychoses of epilepsy (POE). Gambaran psikosis yang
sering ditemukan pada pasien epilepsi adalah gambaran paranoid dan
schizophrenia-like. Pada forced normalization yaitu penderita mengalami
gejala psikotik pada saat kejang terkontrol dan justru gejala psikotik
menghilang bila terjadi kejang.
(https://www.epilepsy.com/learn/challenges-epilepsy/moods-and-
behavior/mood-and-behavior-101/psychosis)
B. Epidemiologi
Berdasarkan penelitian (Maurice dkk. 2014) terkait prevalensi
psikosis pada epilepsi terdapat 215 penelitian mengenai psikosis pada
epilepsi namun hanya 58 penelitian yang relevan (28%) dan sisanya 157
penelitian dilakukan ekslusi. Berdasarkan data didapatkan hasil prevalensi
gangguan psikosis pada pasien epilepsi 5,6-12 % (Puncak 7%).
Berdasarkan regio, komparasi psikosis epilepsy dan non-epilepsi 4,7% di
Inggris dan 9,7% di wilayah Amerika. Sekitar 30% atau 1/3 pasien
epilepsi yang mengunjungi klinik rawat jalan di Amerika mempunyai
riwayat dirawat inap minimal satu kali karena masalah psikiatri. Dan 18%
pasien epilepsi sedang menggunakan paling tidak satu jenis obat
psikotropika. Kira-kira 60% pasien kejang parsial mengalami fenomena
aura, 15% pasien mengalami disforia. Rasa takut yang meningkat menjadi
4
panik juga sering terjadi, kira-kira 20% dari pasien epilepsi fokal
mengalami gangguan afek iktal berupa rasa takut, cemas, dan depresi.
Berdasarkan penelitian interictal psychosis pada epilepsy sekitar
5,2% dan postictal psychosis pada epilepsy sekitar 2%. Gejala psikosis
paling sering dihubungkan dengan epilepsi lobus temporal kanan.Pada
penelitian temporal lobektomi dimana dilakukan operasi pengangkatan
fokus epileptikum, psikosis terjadi pada 7%-8% pasien bahkan jauh
setelah gejala kejangnya sendiri berhenti. Hal ini mengindikasikan
proporsi 2-3 kali lipat munculnya gangguan psikotik pada pasien epilepsi
dibandingkan dengan populasi umum, khususnya pada pasien epilepsi
dengan fokus temporomediobasal.
https://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-14-75
C. Faktor Predisposisi
Faktor predisposisi terjadinya psikosis pada pasien epilepsy adalah
sebagai berikut:
1. Awitan usia muda (pubertas)
2. Kejang berlanjut menahun
3. Perempuan
4. Tipe kejang parsial kompleks, automatisme
5. Frekuensi kejang
6. Lokus fokus epilepsi (temporal)
7. Abnormalitas neurologic
8. Gangliogliomas, hamartoma
Beberapa faktor predisposisi lain adalah lingkungan tempat pasien
tumbuh besar mungkin mengjalangi perkembangan sosial dan fungsi
intelektualnya. Penyebab atau elemen dari lingkungan ini dapat berupa
proteksi berlebihan dari orangtua, regimen pengobatan yang ketat sehingga
menghalangi pasien untuk beraktivitas (bergaul dan berolahraga).
Kejadian kejang berulang yang dapat memunculkan stigma sosial,
pembatasan, dan pandangan bias dapat secara bermakna menekan rasa
5
percaya diri dan membatasi pasien dalam bidang akademik, pekerjaan, dan
kegiatan sosial. Gangguan emosional seperti keadaan frustasi, tegang,
cemas, takut, eksitasi yang hebat dapat mencetuskan serangan epilepsi dan
memperbanyak jumlah serangan epilepsi. Keadaan ini sering dijumpai
pada pasien epilepsi remaja atau dewasa muda.
https://jnnp.bmj.com/content/69/1/1
D. Patofisiologi
6
Obat-obatan anti epilepsi dapat berperan dalam menimbulkan efek
psikosis khususnya pada penderita dengan faktro resiko seperti riwayat
keluarga dengan keluhan yang sama dan adanya riwayat penyakit
psikiatrik terdahulu. Psikosis tercatat memiliki potensi kuat dengan efek
berlawanan pada berbagai obat antiepilepsi dikarenakan obat-obatan yang
tersedia kurang spesifik. Obat-obatan antiepilepsi termasuk ethosuxamide,
topiramate, vigabatrin, zonisamide dan leviteracetam. Satu kasus
ditemukan data prevalensi psikosis (3,7%) dengan penggunaan topiramate.
Dosis obat tinggi pada awal terapi dan jadwal titrasi yang cepat pada
pasien rentan dengan adanya riwayat psikiatri sebelumnya dan dengan
epilepsi berat disertai frekuensi kejang yang sering sangat berhubungan
dengan resiko tinggi untuk terjadi.
Namun, ada kemungkinan bahwa epilepsi yang disertai gejala
psikosis dapat terjadi diluar proses etiologi pada umumnya. Temuan
neuropathological, neuroimaging dan abnormalitas genetic pada pasien
dengan skizofrenia dan pasien dengan epilepsy. Pembesaran ventrikel
umum diteukan sebagai akibat episodik psikosis dan epilepsi lobus
temporalis. Adanya defek pada migrasi sel saraf dapat terkait dengan
pembesaran ventrikel dan defek ini berhubungan dengan skizofrenia dan
epilepsi. Dari sudut pandang biologi saraf, deficit area putih dan kelabu
pada lobus temporalis kemungkinan sebagai penyebab epilepsi dengan
psikosis. Defisit tumpang tindih ini juga ditemukan pada skizofrenia,
termasuk struktur medial-temporal tetapi biasanya hingga lateral-tempiral
dan region ekstratemporal.
Terkait genetik dapat pula berperan berdasarkan mutasi genetic
langka yang dapat menyebabkan epilepsi maupun skizofrenia. Delesi
mikro pada area genomic 15q 13-14 yang terdapat reseptor nikotin yang
berhubungan dengan kejadian skizofrenia atau epilepsi juvenile parsial
autosomal dominan dengan fitur audiotory, dapat pula berperan pada
regulasi transmisi glutaminergik sinapsis, proses yang dapat berkembang
sebagai patofisiologi dari skizofrenia. Kode genetic pada kanal ion dapat
7
menjadi penyebab. Gangguan pada kanal ion diketehui dapat
menyebabkan epilepso dan menunjukkan variasi gen CACNA1C (subunit
dari tipe-L canal kalsium) yang berhubungan dengan skizofrenia
begitupula depresi dan kelainan afektif bipolar.
https://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-
14-75
David AS, Fleminger S, Kopelman MD, Lovestone S, Mellers JDC: Lishman's
Organic Psychiatry. 2010, Oxford: Wiley-Blackwell, Fourth
Fazel S, Lichtenstein P, Grann M, Goodwin GM, Langstrom N: Bipolar disorder
and violent crime: new evidence from population-based longitudinal studies and
systematic review. Arch Gen Psychiatry. 2010, 67 (9): 931-938.
10.1001/archgenpsychiatry.2010.97.
Craddock N, Owen MJ: The Kraepelinian dichotomy - going, going… but still not
gone. Br J Psychiatry. 2010, 196 (2): 92-95. 10.1192/bjp.bp.109.073429.
Lax Pericall MT, Taylor E: Psychosis and epilepsy in young people. Epilepsy
Behav. 2010, 18 (4): 450-454. 10.1016/j.yebeh.2010.05.017
Jones NC, Martin S, Megatia I, Hakami T, Salzberg MR, Pinault D, Morris MJ,
O'Brien TJ, van den Buuse M: A genetic epilepsy rat model displays
endophenotypes of psychosis. Neurobiol Dis. 2010, 39 (1): 116-125.
10.1016/j.nbd.2010.02.001.
Elliott B, Joyce E, Shorvon S: Delusions, illusions and hallucinations in epilepsy: 2.
Complex phenomena and psychosis. Epilepsy Res. 2009, 85 (2–3): 172-186.
Mula M, Monaco F: Antiepileptic drugs and psychopathology of epilepsy: an
update. Epileptic Disord. 2009, 11 (1): 1-9.
Sundram F, Cannon M, Doherty CP, Barker GJ, Fitzsimons M, Delanty N, Cotter
D: Neuroanatomical correlates of psychosis in temporal lobe epilepsy: voxel-
based morphometry study. Br J Psychiatry. 2010, 197 (6): 482-492.
10.1192/bjp.bp.110.080218.
Vassos E, Collier DA, Holden S, Patch C, Rujescu D, St Clair D, Lewis CM:
Penetrance for copy number variants associated with schizophrenia. Hum Mol
Genet. 2010, 19 (17): 3477-3481. 10.1093/hmg/ddq259.
8
E. Manifestasi Klinis
1. Psikosis Iktal
Merupakan tipe dari nonconvulsive status epilepticus, terjadi selama
bangkitan epileptik atau status epileptikus, dan pemeriksaan EEG
merupakan pilihan untuk diagnosis.
a) Iktal dengan gejala psikis
b) Status non konvulsif kehjang parsial simpleks (tipe sensorik, psikis,
motorik, dan autonomi). Kejang parsial kompleks, dan serangan
epileptiform lateralisasi periodik.
https://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-14-
75
Gejala yang nampak adalah sebagai berikut :
a) Iritabilitas
b) Keagresifan
c) Otomatisme
d) Mutisme
Kecuali pada kasus status parsial sederhana, keadaan perasaan
umum menjadi buruk. Kebanyakan dari psikosis iktal mempunyai fokus
epileptiknya pada lobus temporal, hanya 30% focus epileptiknya berada
selain di lobus temporal (korteks frontalis). Adakalanya psikosis menetap
meskipun masa iktal telah selesai.
Penggunaan EEG sangat penting untuk menegakkan diagnosis,
psikosis iktal sering terjadi diluar kesadaran dan pergerakan otomatis
dapat terjadi pada kelainan psikotik yang tidak berhubungan dengan
kejang,
https://www.epilepsy.com/learn/challenges-epilepsy/moods-and-
behavior/mood-and-behavior-101/psychosis
9
kesadaran. Kejadiannya diperkirakan 9% dari semua populasi penderita
epilepsi dan mulai dari usia 30 tahun. Gejala yang timbul :
a) Waham kejar dan keagamaan (onset yang tersembunyi)
b) Halusinasi audiotorik
c) Gangguan moral dan etika
d) Kurang inisiatif
e) Pemikiran yang tidak terorganisasi dengan baik
f) Perilaku agresif
g) Ide bunuh diri
https://www.epilepsy.com/learn/challenges-epilepsy/moods-and-
behavior/mood-and-behavior-101/psychosis
10
a) Halusinasi (auditorik, visual, taktil)
b) Perubahan perilaku seksual
c) Waham (keagamaan, kebesaran, kejar)
https://www.epilepsy.com/learn/challenges-epilepsy/moods-and-
behavior/mood-and-behavior-101/psychosis
F. Penatalaksanaan
Dalam pengobatan epilepsi dengan gangguan psikiatri, yang harus
diperhatikan adalah
1) Antikonvulsan (karbamazepin, asam valproat, gabapentin, dan
lamotigine).
2) Antipsikosis
3) Potensi terjadinya interaksi obat
4) Operasi
11
Aspek khusus: neuroleptik tipikal dan atipikal, AP provoke
electroencephalographic alterations without clinical repercussions in
approximately 7% of users without previous history of epilepsy, and
seizures in 0.5 to 1.2% of these subjects AP are traditionally classified
as typical (or conventional) and atypical. In both classes, the most
important pro-convulsant factors are their different pharmacodynamic
proprieties such as the affinity profile for neuroreceptors and the
specific sites of action, if predominantly cortical, nigro-striatal or
hippocampal.
Conclusion
POE are essentially classified by their temporal relation with epileptic events,
as the clinical presentation can be usually pleomorphic and hardly
distinguishable. Regarding the pharmacological treatment, one of the
limitations of this study was the non-controlled nature of the clinical
observations. Therefore, recommendations to use this or that AP should
always be interpreted cautiously. Other aspect was that almost all studies
which assessed the risk of convulsions induced by AP were performed with
psychiatric patients without epilepsy. Therefore, we believe that future
investigations should include controlled studies and preferentially be
performed with subjects with epilepsy and psychiatric comorbidity.
The pharmacological treatment of POE has particularities, not only due to the
AP/AED interaction, but also because psychosis can suffer the influence of an
epileptic syndrome. Therefore, a sudden change in the pharmacological
treatment of epilepsy (reduction, increase or substitution of AED) should be
avoided, mainly in cases in which there is history of psychoses. Although the
AP/DAE interactions are not yet totally understood, mainly regarding novel
drugs, the knowledge on some aspects of the utilization of AP in epilepsy,
such as their propensity to alter the ET and interactions with the AED, can be
reflected in the therapeutic success.
Guarnieri, Ricardo, Hallak, Jaime Eduardo Cecílio, Walz, Roger, Velasco, Tonicarlo
Rodrigues, Alexandre Júnior, Veriano, Terra-Bustamante, Vera Cristina, Wichert-Ana,
Lauro, & Sakamoto, Américo Ceiki. (2004). Pharmacological treatment of psychosis in
epilepsy. Brazilian Journal of Psychiatry, 26(1), 57-61. https://dx.doi.org/10.1590/S1516-
44462004000100014
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-
44462004000100014&lng=en&nrm=iso&tlng=en
12
Pharmacological management of psychotic
symptoms in epilepsy
Studies on the treatment of psychotic disorders in epilepsy are scant. During the
last 10 years, a couple of consensus papers from internal experts in the field have
been published37,38 providing some guidance to clinicians. However, at the
moment, it seems reasonable to follow internationally adopted guidelines for
treatment outside epilepsy, adapting them to the individual needs of patients with
epilepsy and to the specific clinical scenario.39 Obviously, it is still unknown
whether patients with epilepsy present with the same response and remission rates
of people with schizophrenia. For all these reasons, patients with epilepsy and
psychotic disorders need to be carefully monitored.
Antipsychotics
As already alluded to, the evidence for the use of antipsychotics in epilepsy is
more than limited. According to a Cochrane Review on this subject,40 there is a
single, randomized, controlled study comparing olanzapine (10 mg/day) with
haloperidol (12 mg/day) in 16 people with schizophrenia-like psychosis of
epilepsy, favouring olanzapine. This, however, was published more than 15 years
ago, as a conference abstract and the study were never published in a peer-
reviewed journal. For this reason, as previously stated, standard guidance for
treatment should be followed in people with epilepsy.
According to the National Institute for Health and Care Excellence (NICE;
Clinical Guidance 178), the choice of the antipsychotic medication for a first-
episode psychosis should take into account the likely benefits and possible side
effects of each drug, including metabolic (i.e. weight gain and diabetes),
extrapyramidal (i.e. akathisia, dyskinesia and dystonia), cardiovascular (i.e. long
QT) and hormonal (i.e. increased prolactin levels) side effects.41 Guidelines from
the World Federation of Biological Psychiatry (WFSBP)42 recommend either
olanzapine, quetiapine or risperidone as first-line treatment for first-episode
schizophrenia and this is based on full evidence from controlled studies on a
balance of safety and efficacy data. In fact, clozapine and haloperidol have the
same level of evidence in terms of efficacy but they are both burdened by a lower
tolerability.42
13
In the case of an acute relapse, the WFSBP guidelines state that both FGAPs and
SGAPs have been shown as equally effective and the antipsychotic selection
should be undertaken individually, taking into account the patient’s experience
with certain drug classes and the individual side-effect profile. Before switching
to another antipsychotic drug, a treatment trial at the optimal dose should last for
at least 2 weeks but no longer than 8 weeks, unless unacceptable side effects
occur.
In terms of choice of the antipsychotic agent, clinicians should bear in mind the
risk of pharmacokinetic and pharmacodynamic interactions and seizure risk.
14
especially for drugs like olanzapine and clozapine which have a complex
metabolism with multiple enzymatic pathways involved.47
Table 2. Similar side effects reported for both antipsychotics and antiepileptic
drugs leading to potentially negative pharmacodynamic interactions.
15
View larger version
All these data come from people with primary psychiatric disorders; whether
these findings can be applied to people with epilepsy is still unknown. In the case
of clozapine, there are some data suggesting that the prevalence of seizures is
higher in patients with a previous history of seizures as compared with those
without.53 However, it is unknown whether seizure-free patients on a stable
regime with AEDs present a higher risk as compared with the general population.
16
Regarding the duration of treatment, interictal psychotic episodes in epilepsy are
more likely to be recurrent than in primary schizophrenia38 and, for this reason,
many patients with epilepsy and psychotic disorders tend to be on a long-term
treatment. However, there are no studies specifically investigating this point and
data from retrospective studies suggest that approximately 15% of interictal
psychotic episodes may be self-limiting, with no need for antipsychotic
treatment.55 For this reason, duration of treatment after a first psychotic episode
should follow international guidelines outside epilepsy.
Benzodiazepine
Lithium
Conclusions
17
Psychotic disorders represent a relatively rare but serious comorbidity in epilepsy.
The first step in managing psychotic symptom in epilepsy is to clarify the clinical
context where these symptoms occur, especially if they have a clear relationship
with seizure activity or with the antiepileptic treatment. Given the lack of
evidence-based options for interictal psychoses, internationally adopted guidelines
of treatment should be followed. In particular, risperidone can be considered first-
line treatment, given the low propensity for drug–drug interactions and the low
seizure risk. Pharmacokinetic interactions involve mainly quetiapine, as its
clearance is highly dependent on the CYP 3A4. Combining drugs with a similar
toxicity spectrum may lead to intolerable side effects; for this reason, both
neurologists and psychiatrists need to be aware of the common side effects of both
antiepileptic and antipsychotic drugs. Clozapine should be used in selected cases,
when clinically indicated, but a slow titration regime and close clinical monitoring
is recommended. In postictal psychoses, benzodiazepines, especially clobazam, in
combination with antipsychotics, still represent a very popular treatment option
despite evidence being almost nonexistent. Lithium is rarely used but can be
safely prescribed in the majority of patients.
https://journals.sagepub.com/doi/full/10.1177/2045125319862968
G. Prognosis
18
BAB III
KESIMPULAN
Concluding remarks
In general, psychotic illness in PWEs has been subcategorized into IIP and PIP.
However, while PIP constitutes a rather homogenous clinical entity, IIP is
apparently quite heterogeneous. Most often, IIP is subdivided into chronic and
acute interictal types, with the latter comprising also patients with alternative
psychosis [Tadokoro and Kanemoto, 2012; Trimble, 1991].
In Table 9, data derived from our series of 200 PWEs and psychosis is rearranged
as a function of the closeness of the association with TLE. Interestingly, just as
PIP is quite closely associated with TLE, most PWEs whose initial psychotic
episodes began with repetitive episodic IIP and who ultimately became
continuously psychotic showed extremely high affinity with TLE. To be noted,
this group of patients showed a long interval between psychosis and epilepsy
onset, just as those with PIP.
Table 9.
TLE (%)
19
TLE (%)
*
p = 0.002; **p = 0.005
AIP, acute interictal psychosis; PIP, postictal psychosis; CP, chronic psychosis;
TLE, temporal lobe epilepsy.
Table 10.
Long or
Acute or Affinity Main
Evolution of psychosis short Case
chronic with TLE determinant
interval*
20
Long or
Acute or Affinity Main
Evolution of psychosis short Case
chronic with TLE determinant
interval*
ultimately resulting in CP
Alternative psychosis CP
Acute / Relatively Genetic
C without preceding Short 1
Chronic low predisposition
transient psycotic episodes
*
Interval between psychosis and epilepsy onset.
CP, chronic psychosis; PIP, postictal epilepsy; PWE, patient with epilepsy; TLE,
temporal lobe epilepsy.
Last, but not least, it should be stressed that psychotic disorders in PWEs are often
overlooked, mistreated, and consequently lingering on needlessly [Cornaggia et
al. 2002]. These failures stem mainly from two sources. The first is based on
misdiagnosis. Mild, beginning psychoses are often mistaken for simple depression
and given antidepressants, which are not very effective against psychosis. This
delay of administration of dopamine-blockers may well complicate the situation
seriously. The other problem is more controversial. Some antiepileptic drugs, such
as vigabatrin [Weber et al. 2012], phenytoin, zonisamide [Noguchi et al. 2012],
and topiramate [Khan et al. 1999], have been reported to show adverse
psychotropic effects. If these suggestions are reliable enough, replacement of
these antiepileptics in the case of the occurrence of psychosis seems to be
mandatory. However, robust arguments against this noxious drug theory have
been constantly provided [Mula and Trimble, 2003]. According to the
investigators in support of this line of arguments, it is freedom from seizures in
patients with particular clinical backgrounds that matters, not adverse effect
profiles of individual antiepileptic drugs. To elucidate the riddle of alternative
psychosis, we desperately require further reliable data.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487530/
Adachi N., Akanuma N., Ito M., Kato M., Hara T., Oana Y., et al. (2010) Epileptic, organic
and genetic vulnerabilities for timing of the development of interictal psychosis. Br J
Psych 196: 212–216 [PubMed] [Google Scholar]
Kanemoto, K., Tadokoro, Y., & Oshima, T. (2012). Psychotic illness in patients with
epilepsy. Therapeutic advances in neurological disorders, 5(6), 321–334.
doi:10.1177/1756285612454180
21
DAFTAR PUSTAKA
1. https://www.epilepsy.com/learn/challenges-epilepsy/moods-and-
behavior/mood-and-behavior-101/psychosis
22